Allorion raises $50M Series B; AskBio gets a new CEO
Allorion Therapeutics has raised another $50 million in a Series B financing round to get Phase I/II clinical trials in both China and the US off the ground, the oncology and autoimmune disease-focused biotech announced Thursday.
The biotech has raised $90 million since its beginning in 2020 with co-founders Peter Ding and Fang Li. Gregory Berk has also joined Allorion as CMO to design and oversee the trials and build out the clinical teams in the company’s locations in the US and China.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters